| 前收市價 | 51.10 |
| 開市 | 無 |
| 買盤 | 48.30 |
| 賣出價 | 50.90 |
| 拍板 | 12.50 |
| 到期日 | 2024-12-20 |
| 今日波幅 | 51.10 - 51.10 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 1 |
ZacksApellis' (APLS) Syfovre Boost Sales, Regulatory Setbacks a Woe
Apellis' (APLS) revenues rise on the back of the robust uptake of Syfovre for the GA indication. However, the recent regulatory setback in the EU for pegcetacoplan to treat GA is a woe.
ZacksApellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug
Apellis (APLS) declines as CHMP issues a second negative opinion for the approval of intravitreal pegcetacoplan to treat GA in the EU. The company plans to seek re-examination of the same.
ZacksApellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.
